TITLE

Asthma treatment cost to rise with inhaler ban

AUTHOR(S)
Hirschman, Carolyn
PUB. DATE
November 2005
SOURCE
Employee Benefit News;11/1/2005, Vol. 19 Issue 14, p44
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the anticipated increase in the cost of treating asthma in the U.S. following the gradual shift of the market from albuteril inhalers that contain chlorofluorocarbons (CFC) to those with hydrofluoroalkane. Reasons behind the decision of the Food and Drug Administration to ban the use of inhalers containing CFC; Effect of the shift on low-income and uninsured patients; Impact of the ban of inhalers containing CFC on private health plans and their clients.
ACCESSION #
18746543

 

Related Articles

  • FDA: Patients Should Change Inhalers Ahead of Phaseout.  // Clinician Reviews;Jul2008, Vol. 18 Issue 7, p16 

    The article reports on the public health advisory issued by the U.S. Food and Drug Administration (FDA) to alert patients with asthma, their caregivers and health care professionals to switch to hydrofluoroalkane (HFA)-propelled albuterol inhalers. The move was made because chlorofluorocarbon...

  • FDA Approves New Inhaler Without CFCs.  // FDA Consumer;Jul/Aug2001, Vol. 35 Issue 4, p3 

    Reports on the approval given by the United States Food and Drug Administration to Ventolin HFA (hydroflouroalkane), a metered-dose inhaler for asthma and obstructive lung diseases. Advantage of HFA from other inhalers with chlorofluorocarbons (CFC); Effect of CFC-propelled aerosol products on...

  • FDA Issues Final Rule to Phase Out All Chlorofluorocarbon Inhalers.  // American Family Physician;5/15/2010, Vol. 81 Issue 10, p1193 

    The article reports on the phase out of all chlorofluorocarbon (CFC) inhalers by 2013, according to the U.S. Food and Drug Administration.

  • Zone in on: Regulation. Drakulich, Angie // Pharmaceutical Technology;May2010, Vol. 34 Issue 5, p25 

    The article discusses the move of the U.S. Food and Drug Administration (FDA) to phase-out the seven remaining chlorofluorocarbons (CFC)-containing inhalers on the market.

  • Bronchial thermoplasty cuts asthma exacerbations.  // Patient Care for the Nurse Practitioner;Jun2007, Vol. 10 Issue 6, p12 

    This section presents information on medical studies. Heat-controlled reduction of smooth muscle mass in the airways via bronchial thermoplasty is beneficial to patients with asthma. A study conducted in the U.S. suggests that after 2008, chlorofluorocarbon (CFC)-containing metered-dose inhalers...

  • Final Count Down to HFA Albuterol Inhalers: Are We Ready as Yet? Butt, Ahmed T.; Kamat, Deepak; Pansare, Milind // Clinical Pediatrics;Mar2009, Vol. 48 Issue 2, p131 

    The article reports on the mandated withdrawal of the chlorofluorocarbon (CFC) albuterol inhalers by the U.S. Food and Drug administration (FDA). It states that the CFC has long been used in treating asthmatics. It mentions that after December 31, 2008, the CFC albuterol metered-dose inhalers...

  • Inhalers containing chlorofluorocarbons will soon be phased out.  // Infectious Diseases in Children;May2010, Vol. 23 Issue 5, p40 

    The article reports that the U.S. Food and Drug Administration (FDA) has announced that selected metered-dose inhalers for asthma and chronic obstructive pulmonary disease will be taken out of the U.S. market as they contain ozone-depleting chlorofluorocarbons.

  • 34 Months & Counting. Bunch, Debbie // AARC Times;Mar2009, Vol. 33 Issue 3, p66 

    The article discusses a ruling by the U.S. Food and Drug Administration (FDA) that chlorofluorocarbon (CFC)-containing over-the-counter (OTC) epinephrine inhalers will no longer be available by December 31, 2011, and its implications for respiratory therapists (RT). Such inhalers are known to...

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Oct2012 Pharmacology Watch, p2 

    The article provides updates on the actions taken by the U.S. Food and Drug Administration (FDA) as of October 2012. The FDA has approved a delayed-release form of prednisone for the treatment of endocrine, inflammatory, and neoplastic conditions. The agency has approved a chlorofluorocarbon...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics